On July 29th, Pfizer announced that it would follow the lead set by GSK three months previously and divide up its business so as to create a separate unit containing its off-patent (i.e. generic) products. The new division, which is described as the Value...
Pharmstandard’s plans show that not all shareholders are equal
It is always nice to have prejudices vindicated and this week, Pharmstandard delivered a truly impressive illustration of the dangers of doing business in Russia, particularly if you are the minority shareholder of a quoted company. Information about exactly what is going on has...
A, you’re adorable: suddenly Actavis is everybody’s favourite
Actavis appears to be in the centre of a social whirl, with reports emerging that it has been considering a takeover approach from Valeant, a merger offer from Mylan and the purchase of Warner Chilcott*. The first two appear to be connected, with Mylan...
Hikma’s strategy in the balance as it considers strategic options
Hikma’s FY 2012 results, which were out yesterday, made no direct mention of the company’s announcement on March 1st that it might sell its injectables business, but nevertheless provided considerable food for thought about Hikma’s future strategic direction. Analyst interest focused mainly on the...